CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line
- PMID: 7545087
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line
Abstract
CD30 is a transmembrane receptor of the nerve growth factor/tumor necrosis factor receptor superfamily. Its expression associated with Hodgkin's lymphoma and a subset of non-Hodgkin's lymphoma. Recently, its ligand (CD30L) has been cloned. CD30L enhances the proliferation of peripheral T cells and the Hodgkin's cell line HDLM-2 but seems to exert antiproliferative effects on large cell anaplastic lymphoma cell lines. Since tyrosine kinases are critical regulators of cell growth, we investigated whether CD30L induced changes in cellular tyrosine phosphorylation in CD30-positive lymphoma cell lines. Stimulation with CD30L or with an agonistic mAb against CD30, M44, induced a rapid, transient, and concentration-dependent tyrosine phosphorylation of a cytosolic protein of M(r) 42,000 (p42) in the Hodgkin's lymphomas cell line HDLM-2 but not in other CD30-positive lymphomas. In HDLM-2 cells, the phrobol ester phorbol 12-myristate 13-acetate also stimulated tyrosine phosphorylation of p42, and this effect was enhanced by M44. In marked contrast, agents stimulating the protein kinase A pathway, like forskolin or dibutyryl cAMP, did not affect tyrosine phosphorylation of P42. By immunoprecipitation with mAbs against mitogen-activated protein kinase (MAPK; p42ERKII), a M(r) 42,000 protein was identified which comigrated with p42 on SDS gels and which was phosphorylated on tyrosine residues in response to stimulation of CD30. Immune complex kinase assays showed that M44 mAb induced the activation of MAPK (p42ERKII) and the phosphorylation of a MAPK substrate, myelin basic protein. Taken together, the results suggest that CD30L induces the tyrosine phosphorylation and activation of the MAPK p42ERKII isoform in HDLM-2 cells. These findings may have implications for the understanding of the pathogenesis of Hodgkin's disease.
Similar articles
-
Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia. 1994 Dec;8(12):2083-94. Leukemia. 1994. PMID: 7528856
-
Rapid activation of mitogen-activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells.Cell Growth Differ. 1995 Oct;6(10):1235-44. Cell Growth Differ. 1995. PMID: 8845300
-
[Studies on cell signaling immunomodulated murine peritoneal suppressor macrophages: LPS and PMA mediate the activation of RAF-1, MAPK p44 and MAPK p42 and p38 MAPK].Shi Yan Sheng Wu Xue Bao. 1997 Mar;30(1):73-81. Shi Yan Sheng Wu Xue Bao. 1997. PMID: 10684111 Chinese.
-
CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.Leuk Lymphoma. 1996 Feb;20(5-6):397-409. doi: 10.3109/10428199609052421. Leuk Lymphoma. 1996. PMID: 8833395 Review.
-
Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. Adv Exp Med Biol. 2009. PMID: 19760074 Review.
Cited by
-
TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.Mol Biol Cell. 2015 Mar 1;26(5):993-1006. doi: 10.1091/mbc.E14-08-1290. Epub 2015 Jan 7. Mol Biol Cell. 2015. PMID: 25568342 Free PMC article.
-
CD30 induces Reed-Sternberg cell-like morphology and chromosomal instability in classic Hodgkin lymphoma cell lines.Cancer Sci. 2023 Aug;114(8):3433-3445. doi: 10.1111/cas.15874. Epub 2023 Jun 11. Cancer Sci. 2023. PMID: 37302818 Free PMC article.
-
Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.Lab Invest. 2009 Dec;89(12):1423-32. doi: 10.1038/labinvest.2009.113. Epub 2009 Oct 12. Lab Invest. 2009. PMID: 19823169 Free PMC article.
-
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.Am J Pathol. 2008 Feb;172(2):510-20. doi: 10.2353/ajpath.2008.070858. Epub 2008 Jan 10. Am J Pathol. 2008. PMID: 18187570 Free PMC article.
-
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14053-8. doi: 10.1073/pnas.93.24.14053. Proc Natl Acad Sci U S A. 1996. Retraction in: Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12732. PMID: 8943059 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical